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Abstract Brain inflammation, a common feature in neurode-
generative diseases, is a complex series of events, which can
be detrimental and even lead to neuronal death. Nonetheless,
several studies suggest that inflammatory signals are also pos-
itively influencing neural cell proliferation, survival, migra-
tion, and differentiation. Recently, correlative studies sug-
gested that astrocytes are able to dedifferentiate upon injury
and may thereby re-acquire neural stem cell (NSC) potential.
However, the mechanism underlying this dedifferentiation
process upon injury remains unclear. Here, we report that dur-
ing the early response of reactive gliosis, inflammation in-
duces a conversion of mature astrocytes into neural progeni-
tors. A TNF treatment induces the decrease of specific astro-
cyte markers, such as glial fibrillary acidic protein (GFAP) or
genes related to glycogen metabolism, while a subset of these
cells re-expresses immaturity markers, such as CD44,
Musashi-1, and Oct4. Thus, TNF treatment results in the ap-
pearance of cells that exhibit a neural progenitor phenotype
and are able to proliferate and differentiate into neurons and/or
astrocytes. This dedifferentiation process is maintained as
long as TNF is present in the culture medium. In addition,
we highlight a role for Oct4 in this process, since the TNF-
induced dedifferentiation can be prevented by inhibiting Oct4
expression. Our results show that activation of the NF-κB
pathway through TNF plays an important role in the dediffer-
entiation of astrocytes via the re-expression of Oct4. These
findings indicate that the first step of reactive gliosis is in fact
a dedifferentiation process of resident astrocytes mediated by
the NF-κB pathway.
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Introduction
The most widely recognized form of astrocyte plasticity is the
one which is acquired after injury or during disease states in
the central nervous system (CNS). At sites of ongoing CNS
inflammation, local populations of astrocytes become hyper-
trophic, undergo changes in gene expression, and proliferate
(reviewed in [1–3]). Although the regulation of astrocyte dif-
ferentiation during CNS development is largely described [4,
5], the molecular mechanisms controlling the proliferation of
[6] reactive astrocytes and the formation of the glial scar after
pathological insults are not yet fully understood. Because a
subset of these reactive astrocytes also divides, it has been
suggested that these cells arise from endogenous progenitors
present in the adult brain [7]. Interestingly, a potential dedif-
ferentiation of astrocytes has already been suggested previous-
ly [8]. Recent reports have shown that some astrocytes are
able to acquire stem cell properties upon injury and hence
may provide a promising cell type to initiate repair [9, 10].
In addition, recent in vitro studies have suggested that mature
astrocytes could recover the potential of neural stem cells [11,
12]. These different findings suggest that in the first step of
Electronic supplementary material The online version of this article
(doi:10.1007/s12035-015-9428-3) contains supplementary material,
which is available to authorized users.
* Luc Grandbarbe
luc.grandbarbe@uni.lu
1 Life Sciences Research Unit, Faculty of Science, Technology and
Communication, University of Luxembourg, Campus Limpertsberg,
162A, avenue de la Faïencerie, L-1511 Luxembourg, Luxembourg
2 Luxembourg Centre for Systems Biomedicine, University of
Luxembourg, Campus Belval, 7, avenue des Hauts-Fourneaux,
Esch-Belval, G.D., L-4362 Esch-sur-Alzette, Luxembourg
Mol Neurobiol
DOI 10.1007/s12035-015-9428-3
reactive gliosis, some mature astrocytes undergo morpholog-
ical changes, regain the capacity to proliferate, and become
multipotent progenitor cells, characterized by the expression
of typical stemness markers. In the CNS, neural progenitors
express stemness markers, such as Nestin, Sox2, CD44,
Musashi-1, and Oct4 [13, 14]. It has been suggested that
CD44-positive cells represent astrocyte precursor cells, but
neural stem cells as well as other types of precursor cells do
also express CD44 [15]. Oct4 expression is believed to be
restricted to pluripotent cells [16, 17]. Nevertheless, some re-
ports show that Oct4 is present in neurospheres, which are
composed of neural stem cells and more restricted neural pro-
genitor cells, and that up- or downregulation of Oct4 influ-
ences cell fate and differentiation [18, 19]. In the same way,
Oct4 is strongly expressed in glioma and the expression level
can be positively correlated to increasing glioma grades [20].
Our study shows that inflammation induces a switch of
astrocytes into neural progenitors. In a first step, TNF-
activated astrocytes lose the expression of glial fibrillary acid-
ic protein (GFAP) and genes related to glycogen metabolism.
Simultaneously, they re-express stemness markers, such as
CD44,Musashi-1, and Oct4. This re-expression of immaturity
markers is maintained as long as TNF is present in the culture
medium. In addition, we provide a role for Oct4 in this process
of dedifferentiation. The dedifferentiation induced by TNF
can be prevented by decreasing the expression of Oct4. Our
results show that Oct4 can, at least partially, control this
switch. Thus, the activation of the NF-κB pathway appears
to be a key element in the dedifferentiation process of astro-
cytes, which seems to represent the first step characterizing the
reactive gliosis.
Materials and Methods
Ethics Statement
The experiments involving animals were carried out accord-
ing to the 2010/63 European Union Directive and internal
ethical committee regulations.
Animals
Wild-type male C57Bl/6J mice (Harlan, The Netherlands)
were housed in an air-conditioned room with free access to
water and food, using standard guidelines. Mice were used at
6–8 weeks of age. The mice were randomly dispatched into
six groups of eight mice. In every group, three animals were
used for RNA extractions and three animals for immunohis-
tochemistry analysis. The animal experiments were carried
out in strict accordance with our local Committee for Care
and Use of Laboratory Animals.
Stab Wound Injury and Immunohistofluorescence
The animals were anesthetized with isoflurane and
mounted into a stereotaxic frame (David Kopf Instru-
ments, Tujunga, CA, USA). Stab wound injury was exe-
cuted with phosphate-buffered saline (PBS) or LPS (1 μg/
μl) or TNF (10 ng/μl) in the right primary somatosensory
cortex (S1 of C57BL/6J mice). The wound was inflicted
using a Hamilton syringe (7001 SN 1 μl) left in place
during 5 min at the following stereotaxic coordinates:
2 mm anterior, 2.3 mm lateral, and 2.5 mm ventral to
the bregma. For the kinetic experiments, the wound was
inflicted at the following stereotaxic coordinates:
−1.1 mm anterior, 2.5 mm lateral, and 1.1 mm ventral to
the bregma. Twenty-four hours, 2 days, or 5 days later,
mice were transcardially perfused with PBS. Brains were
gently removed from the skull and embedded in O.C.T.
( S a k u r a F i n e t e k , A J A l p h e n a a n d e n R i j n ,
The Netherlands). For immunohistochemistry labeling,
brains were cut into 10-μm-thick coronal cryosections
and fixed in ice-cold acetone. Sections were stained over-
night with antibodies against GFAP (Sigma; 1:800) and
CD11b (ImmunoTools; 1:100). Then, the slices were in-
cubated with the corresponding secondary antibodies at
room temperature for 1 h (Cy2-conjugated donkey anti-
mouse, Cy2-conjugated donkey anti-rabbit, and Cy3-
conjugated donkey anti-rabbit, Jackson ImmunoResearch;
1:1000). Finally, the brain sections were analyzed under
an inverted confocal microscope.
Cell Culture
Cultures of primary mouse astrocytes were prepared from
brains of postnatal (P0–P2) C57BL/6J mice as previously de-
scribed [21]. Briefly, brain cortices were minced in cold PBS
(pH 7.4) solution. The dissociation was completed by a 10-
min incubation in 1 mM EDTA. The cells were plated and
grown at 37 °C in DMEM supplemented with 10 % fetal
bovine serum (FBS), penicillin (100 U/ml), and streptomycin
(100 μg/ml) in a water-saturated atmosphere containing 5 %
CO2. After 4 days, the medium was replaced by a fresh one,
which was further replaced twice a week. After 10–14 days,
the cultures reached confluence and the microglial cells were
detached by incubating the plates twice on an orbital shaker
during 8 h (200 rpm). Cells were then trypsinized, and
CD11b-positive microglia were sorted out on a magnetic
cell-sorting (MACS) device (Miltenyi Biotec, Bergisch
Gladbach, Germany) as described previously [21, 22]. The
flow-through consisted in negatively selected astrocytes,
which were plated during 4 to 7 days in DMEM supplemented
with 10 % FBS.
Primary cultures of neurospheres were obtained from mu-
rine embryonic neural stem cells derived from the ventricular
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zone (VZ) of embryonic day-14 (E14) C57BL/6J mouse em-
bryos (Harlan) as described previously [23, 24].
Neurospheres were cultured in Neurobasal medium supple-
mented with 2 % B27 w/o vitamin A, 2 mM glutamine, pen-
icillin (100 U/ml), streptomycin (100 μg/ml), and 20 ng/ml
mouse recombinant epidermal growth factor (EGF).
Neurospheres were differentiated into astrocytes by plating
them on poly-L-ornithine-coated flasks filled with DMEM
containing 10% FBS. The cultures reached confluence within
2 weeks. The inflammatory stimulus was triggered by adding
TNF (50 ng/ml) on the cells for 24 h. For semi-clonal exper-
iments of neurosphere-forming assay, after TNF treatment,
astrocytes were dissociated and plated in a 96-well plate (20
cells per well) in Neurobasal medium supplemented with B27
w/o vitamin A, 2 mM glutamine, penicillin (100 U/ml), strep-
tomycin (100 μg/ml), and 20 ng/ml mouse recombinant EGF.
After 1 month, neurospheres (bigger than 100 μm) were
counted.
NF-κB Inhibition
The NF-κB pathway was inhibited using 20 μM of 4-methyl-
N1-(3-phenyl-propyl)-benzene-1,2-diamine (JSH-23)
(Calbiochem, Merck, Darmstadt, Germany), a selective inhib-
itor of nuclear translocation of NF-κB p65. JSH-23 was added
to cells 30 min prior to TNF treatment. The control condition
used for JSH-23 was the vehicle (DMSO 0.05 %).
Real-Time PCR Gene Expression Analysis
Total RNA was extracted by using the Invisorb Spin Cell
RNA Mini Kit (Invitek, Berlin, Germany) or RNA NOW
reagent (Biogentex, Seabrook, TX). For the in vivo experi-
ments, biopsies of the injection area were collected (biopsy
punch, 2 mm in diameter and 1 mm in depth, Miltex) and
RNA extracted. The yield and integrity of RNA samples were
assessed on a NanoDrop1000 device (Thermo Fisher Scien-
tific, Waltham, MA, USA) and a microelectrophoresis device
(Experion RNA StdSens Analysis Kit; Bio-Rad Laboratories,
Hercules, CA, USA). The RNA was reverse transcribed into
cDNA using Im-Prom-II Reverse Transcription System
(Promega, Madison, WI, USA). Polymerase chain reactions
(PCR) were set up in 20-μl reaction volume using PerfeCta
SYBRGreen SuperMix for iQ (Quanta Biosciences, Gaithers-
burg, MD, USA). Primers for each candidate gene were de-
signed using Beacon Designer software (Premier Biosoft In-
ternational, Palo Alto, CA, USA) and used at a final concen-
tration of 500 nM. (See supporting information Table 1 for a
list of primers used.) The relative changes of gene expression
were estimated and normalized to β-actin by using the 2−ΔΔCT
method.
Immunolabeling
Cells were cultured on poly-L-ornithine-coated coverslips for
24 h and then fixed with 4 % paraformaldehyde for 20 min
and permeabilized in PBS containing 0.3 % Triton X-100
(Sigma, St. Louis, MO, USA). The blocking was done using
a PBS solution containing 3 % bovine serum albumin (BSA)
(Sigma). The cells were then incubated overnight at 4 °C with
polyclonal cyanine 3-conjugated mouse anti-GFAP IgG
(1:800) (Sigma), rabbit anti-GFAP IgG (1:800) (Dako,
Glostrup, Denmark), mouse anti-Nestin IgG (1:200)
(Chemicon, Millipore, Billerica, MA, USA), and mouse
anti-MAP2 IgG (1:200) (Chemicon). On the next day, the
coverslips were incubated with species-specific secondary an-
tibodies conjugated to cyanine 2 (Cy2-conjugated donkey an-
ti-mouse, Jackson ImmunoResearch, West Grove, PA, USA)
and cyanine 3 (Cy3-conjugated donkey anti-mouse or Cy3-
conjugated donkey anti-rabbit, Jackson ImmunoResearch)
(1:1000) for 1 h at room temperature. A biotin–streptavidin
signal amplification strategy was performed for low expres-
sion as Oct4, CD44, Musashi-1, and EGFR. Then, the cells
were stained with polyclonal rabbit anti-Oct4 IgG (1:100)
(Abcam), rabbit anti-CD44 IgG (1:50) (Abcam), rabbit anti-
Musashi-1 (1:100) (Abcam), and rabbit anti-EGFR (1:50)
(Abcam) and sequentially incubated with biotinylated anti-
r abb i t secondary an t ibod ies (1 :1000) ( Jackson
ImmunoResearch) and Cy2-conjugated streptavidin. Prepara-
tions were counterstained with DAPI (1:10,000, Molecular
Probes) and mounted with Aquamount on glass slides (South-
ern BioTech). Photomicrographs were acquired with a LSM
510 META inverted confocal microscope (Carl Zeiss Micro
Imaging, Göttingen, Germany).
Microarray Experiments and Quality Control
Cultures of primary mouse astrocytes were treated with TNF
(50 ng/ml) for 24 h. Cells were collected and immediately
homogenized in cooled-down RNANOWreagent (OZYME).
Total RNAwas extracted according to RNA NOW manufac-
turer’s recommendations with −20 °C overnight incubation
for small RNA precipitation. Total RNA integrity and purity
were assessed using the Agilent 2100 Bioanalyzer and RNA
6000 Nano LabChip kits (Agilent Technologies). Only good-
quality RNA (no contamination or degradation, RIN>9) was
used and further processed. Total RNA samples were reverse
transcribed to double-stranded cDNA using specific primers,
which reduce the priming of rRNA. cRNAwas generated by
in vitro transcription and reverse transcribed into a sense
single-stranded cDNA. The cDNA was fragmented, labeled,
and hybridized onto Affymetrix GeneChip Mouse Gene 1.0
ST arrays according to the Ambion Whole Transcript Expres-
sion kit for Affymetrix GeneChip Whole Transcript Expres-
sion Array Protocol (P/N 4425209 Rev.B 05/2009) and
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GeneChip WT Terminal Labeling and Hybridization User
Manual for use with the AmbionWhole Transcript Expression
kit (P/N 702808 Rev.6). Microarrays were then washed,
stained, and scanned according to the manufacturer’s instruc-
tions. The six CEL files generated by the scanner were then
imported into Partek Genomics Suite (GS) 6.4 for preprocess-
ing and quality control. Preprocessing aims at estimating tran-
script cluster expression values from probe signal intensities.
Thus, Partek options were set up for GC content adjustment,
robust multiarray background correction, quantile normaliza-
tion, log2 transformation, and mean summarization. Quality
control was assessed through different methods available in
Partek GS and did not reveal any outlier. Microarray expres-
sion data are available at the GEO database.
Statistical Analysis and Data Visualization
Data are represented as mean±standard error of the mean
(SEM). Statistical differences between two groups were deter-
mined by nonparametric Mann–Whitney test. Multiple group
comparisons were made using Kruskal–Wallis test with a sig-
nificance level of 95 % followed by Dunn’s post test.
The real-time PCR expression data of time series were
analyzed using the R software (R Foundation for Statistical
Computing; Vienna, Austria). A two-way ANOVA, testing
the effect of Btreatment^ and Btime,^ was performed on the
delta Ct values (the residuals were tested to be normally dis-
tributed and delta Ct values of each group to be homoscedas-
tic). If a factor of more than two levels significantly affected
the dCt values, a Tukey post hoc test was used to determine
the source of the variation. Similarly, the in vivo data were
analyzed by a two-way ANOVA testing the effect of the fac-
tors Btreatment^ and Bhemisphere.^
Microarray gene expression data was normalized using the
GC-RMA procedure with default parameters for background
correction, quantile normalization, and probe replicate sum-
marization [25]. Differentially expressed genes between con-
trol and TNF conditions were then determined using the em-
pirical Bayes moderated t statistic (eBayes) [26]. p value sig-
nificance scores for these genes were adjusted for multiple
hypothesis testing according to the Benjamini–Hochberg pro-
cedure [27].
A heat map and dendrogram cluster visualization for the
top 100 most significant known genes (see Fig. 2a) was ob-
tained using standard hierarchical average linkage clustering
with a Euclidean distance metric. To create network visuali-
zations for the two marker genes of interest, GFAP and gly-
cogen phosphorylase (Pygb), interactions of the correspond-
ing proteins were retrieved from the STRING database [28]
using only protein–protein interactions with a minimum con-
fidence score of 900 out of a maximum of 1000 (see Fig. 2b,
c). Next, the layout of the network representations was gener-
ated by applying 1000 iterations of the Fruchterman–Reingold
automated graph layout algorithm [29]. Finally, nodes in these
network graphs were colored such that underexpressed genes
in the TNF samples as compared to the control samples are
represented by blue nodes and overexpressed genes by red
nodes (the color darkness is proportional to the absolute fold
change on a logarithmic scale).
Alterations in known cellular pathways and processes were
identified and visualized by applying the MetaCore™
GeneGO software onto the differential expression statistics
obtained from the eBayes analysis (see above). The genes
were pre-filtered using a significance threshold (adjusted p
value <0.05) before applying the default GeneGO pathway
analysis. In the resulting pathway visualizations,
underexpressed genes in the treated samples are highlighted
by a blue bar and overexpressed genes by a red bar (the length
of the colored bar next to each gene represents the absolute
fold change on a logarithmic scale).
Results
TNF Induces the Re-expression of Markers of Stemness
State in Neurosphere-Derived Astrocytes
In order to determine whether inflammation could convert
astrocytes to a more immature state, we first studied the dif-
ferentiation kinetics of neural progenitors to astrocytes by
Table 1 qPCR primers
Forward Reverse
Actb 5′-AGGGAAATCGTGCGTGACATCAAGAG-3′ 5′-GGAGGAAGAGGATGCGGCAGTGG-3′
Oct4 5′-ACCACCATCTGTCGCTTC-3′ 5′-CTCATTGTTGTCGGCTTCC-3′
Cd44 5′-TGGCACTGGCTCTGATTC-3′ 5′-GTCTCTGATGGTTCCTTGTTC-3′
Gfap 5′-GGTTGAATCGCTGGAGGAG-3′ 5′-CTGTGAGGTCTGGCTTGG-3′
Egfr 5′-TAATGTCTGCCACCTATGC-3′ 5′-GCCACCACCACTATGAAG-3′
Sox2 5′-CGCAGACCTACATGAACG-3′ 5′-TCGGACTTGACCACAGAG-3′
GlyPH 5′-GCTGCTCAACTGCCTACACATT-3′ 5′-AACAGTCCTGGGCACAAAGG-3′
Ptg 5′-TCGCAGAGTGAGTGGAA GAGC-3′ 5′-CTTGGAGTCCGCAAACACG-3′
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protein expression levels of stemness markers. As shown in
previous studies, neurospheres differentiated in the presence
of 10%FBS finally form a flat layer of astrocytes [23]. During
the first days of differentiation, the expression of stemness
markers, such as Oct4, CD44, and EGFR, decreased and
was correlated to an increase in GFAP expression (Fig. 1a).
Oct4, CD44, and EGFR were detected on progenitor cells
in vitro. After 3 h of differentiation, all progenitor cells (in
the periphery of the neurospheres) were still positive for
Oct4, CD44, and EGFR staining (Fig. 1a). After 1 day of
differentiation, even though the cells began to express GFAP,
we could observe that the expression of Oct4 and CD44
persisted in astrocyte-restricted precursor cells (Fig. 1a). In
contrast, after 2 days of differentiation, the majority of differ-
entiated cells expressed GFAP, while losing the expression of
stemness markers. At this time point, Oct4, CD44, and EGFR
were no longer detected (Fig. 1a). These results show that
stemness markers such as Oct4, CD44, and EGFR expressed
in neural stem cells and progenitor cells persist in astrocyte-
restricted precursor cells but are absent in GFAP-expressing
astrocytes.
In order to determine the effect of inflammation on differ-
entiated astrocytes, neurosphere-derived astrocytes were treat-
ed with TNF after 2 weeks of differentiation. In untreated and
TNF-treated neurosphere-derived astrocytes, Oct4, Sox2,
CD44, EGFR, and GFAP transcript expression levels were
measured by real-time PCR. We observed important modula-
tions in Oct4, Sox2, CD44, and EGFR mRNA expression
when cells were activated with TNF (Fig. 1b). After 24 h,
Oct4, Sox2, CD44, and EGFR expression increased in TNF-
activated cells (Fig. 1b). In contrast, GFAP expression de-
creased slightly under the same conditions (Fig. 1b). At the
protein level, we were also able to observe the re-expression
of stemness markers following TNF treatment (Fig. 1a). These
results show that TNF induces the conversion of mature as-
trocytes into a more immature state.
TNF Induces the Re-expression of Markers of Stemness
in Primary Astrocytes
Although neurosphere-derived astrocytes can be considered
as a microglia-free alternative to primary astrocyte cultures,
we wanted to confirm our observations on mixed glial culture
derived-astrocytes. Mixed glial cultures contain mostly astro-
cytes but also a variable amount of contaminating microglia
(CD11b-positive cells). We negatively selected astrocytes
with the MACS technology by using anti-CD11b antibody-
coupled microbeads to eliminate the microglial cell popula-
tion. To confirm the previous results obtained with
neurosphere-derived astrocytes, we treated primary astrocytes
with TNF (50 ng/ml for 24 h). Microarray analysis of primary
astrocytes treated for 24 h with TNF showed that the NF-κB
pathway and its related inflammatory signaling were strongly
induced (Fig. 2). Moreover, pathway analysis with GeneGO
revealed that pathways related to glial differentiation were
modulated (Fig. 3). Network visualizations of two marker
genes of interest, GFAP and glycogen phosphorylase (Pygb),
highlighting interactions of the corresponding proteins and
expression alterations in their coding genes, confirmed that
the astrocyte phenotype is changing under inflammatory con-
ditions (Fig. 3). Using real-time PCR, we checked whether
TNF initiates the conversion of mature astrocytes to a more
immature state. As for neurosphere-derived astrocytes, we
could observe that on primary astrocytes, a TNF treatment
was able to significantly upregulate Oct4 and CD44 expres-
sion, as well as downregulate GFAP, glycogen phosphorylase,
and PTG expression (Fig. 4a). Moreover, this change in ex-
pression of Oct4, CD44, GFAP, glycogen phosphorylase, and
PTG, induced by TNF, was maintained during 4 days
(Fig. 4a). The analysis of TNF-treated primary astrocytes by
confocal microscopy revealed that the activation of the NF-κB
pathway for 24 h was sufficient to induce the expression of
typical neural progenitor cell (NPC) markers such as Oct4,
EGFR, Musashi-1, and CD44 while GFAP expression dimin-
ished (Fig. 4b). On the other hand, untreated astrocytes did not
express these NPC markers with a large number of cells re-
maining GFAP positive (Fig. 4b). Interestingly, we were not
able to observe any change in Nestin expression after 24 h of
TNF activation (Fig. 4b). When TNF was removed after 24 h
of treatment, expression levels of Oct4, CD44, GFAP, and
PTG after 2 and 5 days returned towards normal levels
(Fig. 4c). To estimate the fraction of cells that are able to
proliferate after 24 h of TNF treatment, we counted Ki67-
positive cells. No difference was observed between control
and TNF-treated astrocytes (4.7 % in control conditions and
2.9 % in TNF-treated astrocytes).
To demonstrate that astrocytes treated with TNF present
some characteristics of neural progenitors, we examined the
differentiation potential of cells reacting to inflammation
using a neurosphere-forming assay (see Fig. 5a for experimen-
tal design). Whereas few neurospheres were generated from
cells isolated from a primary astrocyte culture, cells isolated
from TNF-treated cultures were able to form higher amounts
of neurospheres. In fact, quantitative data obtained from semi-
clonal neurosphere-forming assays show that the percentage
of cells able to generate a neurosphere is doubled in astrocytes
treated with TNF in comparison to control (Fig. 5b). After
dissociation of primary astrocytes, cells treated for 24 h with
TNF and then cultivated for 6 h in neurosphere medium (con-
taining EGF) expressedMAP2 (2A+2B) and Nestin (Fig. 5a).
After 5 days in neurosphere medium, many MAP2 (2A+2B)
and Nestin-positive cells were observed in cultures previously
treated with TNF (26.2 % of cells were MAP2 positive and
32.9 % of cells were Nestin positive) (Fig. 5a). In control
conditions, few cells expressed MAP2 (2A+2B) and Nestin
(5 % of MAP2-positive cells and 8.6 % of Nestin-positive
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cells) (Fig. 5a). These observations confirm that in primary
cultures of astrocytes activated with TNF, some cells are able
to respond to neurosphere medium and produce neural pro-
genitors (Nestin-positive cells) and neurons (MAP2-positive
cells). The absence of oligodendrocyte progenitor cells (iden-
tified with O4 antibody) during the neurosphere assay sug-
gests that neural progenitor cells obtained after dedifferentia-
tion of astrocytes are bipotent. Similar results were obtained
with neurosphere-derived astrocytes, which represent a model
of pure astrocyte culture. Taken together, our in vitro obser-
vations show for the first time that after TNF treatment, a
subset of astrocytes dedifferentiates towards a more immature
state characterized by the re-expression of stemness markers
and the repression of typical astrocyte markers such as GFAP,
glycogen phosphorylase, and PTG. This dedifferentiation pro-
cess is maintained as long as TNF is present in the culture
medium. Once TNF is removed, astrocytes recover their initial
phenotype and are undistinguishable from control astrocytes.
Inflammation Induces Dedifferentiation of Astrocytes
In Vivo
To confirm that the activation of the inflammatory signal-
ing pathway directs the dedifferentiation of astrocytes
in vivo, we realized a kinetic experiment of cortical stab
wound lesions in adult mice. Animals were sacrificed
24 h, 48 h, and 5 days after injury. Frontal sections were
realized in order to assess the phenotype of cells present
in the area of the lesion. After 24 h, on low-magnification
images, CD11b-positive cells corresponding to microglia
were already present within the site of lesion while no
GFAP-positive cells were observed. Nevertheless, some
GFAP-positive cells could be observed at distance of this
area (Fig. 6a). It is noteworthy that the basal GFAP stain-
ing is weak in the healthy mouse cortex. The absence of
GFAP-positive cells in close proximity to the stab wound
lesion persisted during 48 h while the expression of GFAP
increased around this site (Fig. 6a). Five days after injury,
the glial scar seemed completely present as many reactive
astrocytes expressed large amounts of GFAP (Fig. 6a).
Concerning transcript analysis, animals were sacrificed
24 h after the injury to collect biopsies of the lesioned
area and to extract RNAs. Oct4 and CD44 expression
was examined by real-time PCR. Transcript levels of
Oct4 and CD44 were upregulated in the area of the lesion
(ipsilateral) compared to the contralateral area (control)
(Fig. 6b). Frontal sections were also realized 24 h after
the injury in order to assess the phenotype of cells present
Fig. 1 a NSC differentiation to
astrocytes. After 3 h, 24 h, 48 h,
2 weeks, and 2 weeks+TNF (last
24 h TNF treatment, last column)
of neurosphere differentiation,
cells were analyzed by
immunofluorescence for the
expression of Oct4 (upper panel,
green), GFAP (middle panel, red),
and CD44 (middle panel, green).
In the lower panel, cells were
stained for GFAP (red) and EGFR
(green). Scale bar=50 μm. b
TNF induces the re-expression of
markers of stemness state in
neurosphere-derived astrocytes.
Real-time PCRwas used to assess
the regulation of Oct4, CD44,
GFAP, EGFR, and Sox2 in
neurosphere-derived astrocytes.
Gene expression has been nor-
malized to β-actin. n=3; error
bars represent the SEM. *p<0.05
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Fig. 2 Heat map visualization of the normalized gene expression levels
for the top 100 most significant known genes with differential expression
between control and TNF samples according to the empirical Bayes
moderated t statistic [26]. Hierarchical clustering was applied to identify
groups of genes with similar expression profiles (see dendrogram
visualization on the left)
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in the area of the lesion. Consistent with our in vitro data,
we were able to observe Oct4-positive cells in the le-
sioned area (Fig. 6c) in parallel to a decrease of GFAP-
positive cells (Fig. 6c). The use of an astrocyte/low-grade
astrocytoma marker demonstrated that Oct4 is re-
expressed in astrocytes during injury. In fact, this mono-
clonal antibody (Mab JI-31) recognizes an intracellular
protein antigen expressed by astrocytes and upregulated
in reactive astrocytes [30]. Consistent with our hypothe-
sis, the Oct4-positive cells were costained with the J1-31
anti-astrocyte antibody in the area of the lesion (Fig. 6c).
Overall, our in vivo data suggest that in the area of injury
during the very early response, inflammation induces a
transient decrease of GFAP expression in astrocytes cor-
related with the re-expression of stemness markers. These
observations confirm our previous in vitro results.
NF-κB inhibition Antagonizes the TNF-Induced
Dedifferentiation of Reactive Astrocytes In Vitro
Previous results have shown that the aromatic diamine JSH-23
compound has an inhibitory effect on the NF-κB transcrip-
tional activity [31]. The NF-κB inhibitory activity of the JSH-
23 compound in our cells was shown by the reduced expres-
sion of IκBαwhich reflects the activity of the NF-κB pathway
(Fig. 7). To demonstrate that the dedifferentiation induced by
TNF (50 ng/ml) in astrocytes was dependent on NF-κB activ-
ity, we used JSH-23 (20 μM). After 24 h of TNF activation,
primary astrocytes treated with JSH-23 presented a low re-
expression ofOct4,CD44, and EGFRwhen compared to cells
treated with TNF alone (Fig. 7). Our data demonstrate that the
dedifferentiation of astrocytes by TNF depends at least partly
on the NF-κB pathway.
Fig. 3 For the two marker genes of interest, GFAP and glycogen
phosphorylase (Pygb), the local interaction network for the
corresponding proteins was determined using protein–protein
interactions from the STRING database [28] (with a confidence score
of at least 900). Graph representations of these interaction networks
were created using 1000 iterations of the Fruchterman–Reingold
automated graph layout algorithm [29]. Blue nodes represent
underexpressed genes in the TNF samples as compared to the control
samples, and red nodes highlight overexpressed genes (darker colors
reflect larger absolute fold changes on a logarithmic scale). Cellular
pathways and processes identified using the GeneGO pathway analysis
of known genes with significant differential expression between control
and TNF samples
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Fig. 4 TNF induces astrocyte dedifferentiation. a RNA of primary
astrocytes were collected 24 h, 48 h, 3 days, and 4 days after TNF
treatment and analyzed for the expression of Oct4, CD44, GFAP,
glycogen phosphorylase, and PTG by real-time PCR. Gene expression
has been normalized to β-actin. n=3; error bars represent the SEM. b
Primary astrocytes were treated with TNF for 24 h and then fixed and
stained for immunofluorescence. From the upper to the lower panels, we
analyzed the expression of Oct4 and CD44 (green) compared to GFAP
(red). Primary astrocytes were treated with TNF for 3 days and then fixed
and stained for immunofluorescence. We analyzed the expression of
Musashi-1 and EGFR (green) compared to GFAP and Nestin (red). Scale
bar=50 μm. c RNA of primary astrocytes were collected 3 and 6 days
after the initial 24-h TNF treatment and cultivated with or without TNF up
to RNA extraction and analyzed for the expression of Oct4, CD44, GFAP,
and PTG by real-time PCR. Gene expression has been normalized to β-
actin. n=3 independent experiments; error bars represent the SEM.
*p<0.05, **p<0.01, ***p<0.001
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Discussion
Beside the well-established sources of neural stem cells
(NSCs), it was recently shown that astrocytes could be a
source of multipotent cells in the brain [9, 10]. After injury,
during reactive gliosis, some astrocytes acquire stem cell
properties. Reactive gliosis is the reaction to brain injury, but
the precise origin of the glial cells implicated in this response
is still unknown. Astrocytes react to injury by undergoing a
phenotypical transformation characterized by hypertrophy
and cytoskeletal modifications like the upregulation of GFAP
and the re-expression of the progenitor markers vimentin and
Nestin. While it is generally accepted that mature astrocytes
do not normally divide, a subpopulation of reactive GFAP-
positive cells does so, prompting the question of whether the
proliferating GFAP-positive cells arise from endogenous glial
progenitors or from mature astrocytes that start to proliferate
in response to brain injury. Yet, reprogramming or potential
differentiation was already previously suggested [8] and the
work of Buffo and co-workers shows that mature astrocytes
start to proliferate after a stab wound injury and contribute to
the reactive gliosis and proliferation of GFAP-positive cells.
This conversion of somatic cells, like astrocytes, to a
multipotent state by reprogramming, raises a number of mech-
anistic questions. Sharif et al. recently demonstrated that
TGFα promotes the sequential conversion of mature astro-
cytes into neural progenitors [11]. In addition, Yang et al.
showed that astrocyte dedifferentiation is induced in a scratch
wound assay or by conditioned culturemedium collected from
scratch assay astrocytes [12].
In the present study, we provide evidence that TNF-
induced NF-κB stimulation results in the dedifferentiation
of astrocytes in vitro. GFAP is the classical marker used
to identify differentiated astrocytes [32]. However, func-
tional features of mature astrocytes may represent better
markers of terminal differentiation for astrocytes. Glyco-
gen is the major energy reserve of the brain and it is
exclusively localized in astrocytes [33]. After 24 h of
TNF stimulation in vitro, the phenotype of mature astro-
cytes has changed. In fact, astrocytes lose the expression
of GFAP, glycogen phosphorylase, and PTG. For two
marker genes of interest, GFAP and glycogen phosphory-
lase (Pygb), the local interaction network for the corre-
sponding proteins confirms this action of TNF. Interest-
ingly, the increase of expression of Jak-Stat signaling
components (observed in the local interaction network
for GFAP) after TNF stimulation could explain the loss
of GFAP. In fact, overexpression of Jak-Stat signaling is
known to inhibit astrogliogenesis and GFAP expression
[34]. At the same time, a population of astrocytes re-
express immaturity state markers, such as CD44,
Musashi-1, and Oct4. In our conditions, neurosphere-
derived astrocytes treated with TNF increase their expres-
sion of Oct4, CD44, EGFr, and Sox2 after 24 h. It is
interesting to note that this dedifferentiation process is
maintained as long as TNF is present in the culture me-
dium. Once TNF is removed, astrocytes recover the phe-
notype of control astrocytes. When we incubated TNF-
treated primary astrocytes in neurosphere growth medium
containing EGF, we were able to obtain neural progenitors
as well as neuron-like cells. This neurosphere assay en-
forces the hypothesis that TNF induces the conversion of
some astrocytes into neural progenitors. Strikingly, the
absence of oligodendrocyte progenitor cells in this assay
suggests that the hereby obtained neural progenitors are
bipotent and, once differentiated, are only able to generate
neurons and/or astrocytes. Interestingly, Ravin et al previ-
ously described the existence of a bipotent neuron–astro-
cyte progenitor, which derives from the multipotent CNS
stem cell [35]. In addition, the team of D. A. Steindler
Fig. 5 TNF treatment results in the appearance of cells with neural
progenitor phenotype. a Primary astrocytes were treated with TNF for
24 h, dissociated, and re-plated in Neurobasal medium containing EGF
(experimental setup). Afterwards, cells were analyzed by immunocyto-
chemistry. The expression of MAP2 (2A+2B) and Nestin (both in red)
were compared to that of GFAP (green) after 6 h (1) or 5 days (2). Scale
bar=50 μm. b Semi-clonal experiments of the neurosphere-forming as-
say. After TNF treatment, astrocytes were dissociated and plated in a 96-
well plate (20 cells per well) in neurosphere medium. After 1 month,
neurospheres were counted. n=3 independent experiments; error bars
represent the SEM. *p<0.05
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found similar bipotent progenitors, which were not able to
give rise to oligodendrocytes, when placing human cells
from the temporal lobe epilepsy area in growth conditions
favoring the propagation of progenitors [36].
The same results are obtained with pure cultures of
neurosphere-derived astrocytes. The use of two different
models of astrocyte cultures supports the hypothesis of a de-
differentiation of astrocytes while making the possibility of a
contamination with certain neural stem cell populations highly
unlikely. In fact, we never could obtain neurospheres after
dissociation and cultivation in neurosphere medium of
neurosphere-derived astrocytes. These in vitro observations
are, at least partially, confirmed in a mouse model of cortical
lesions. While it is admitted that gliosis is accompanied by an
increase of GFAP, detailed kinetic studies performed in our lab
have shown that this increase of GFAP expression begins only
2 days after injury (Fig. 6a). Interestingly, we observed a tran-
sient decrease of GFAP after 24 h, which persists 48 h after the
injury within the site of lesion. Together, our in vitro and
in vivo data suggest that during the first step of reactive
gliosis, there is a conversion of mature astrocytes into an im-
mature state (GFAP negative, CD44 positive, and EGFR pos-
itive). It is interesting to note that CD44 identifies an
astrocyte-restricted precursor cell that is committed to gener-
ate astrocytes in vitro and in vivo in both rodent and human
tissues [37]. In this population of dedifferentiated astrocytes,
some cells present the characteristic markers of neural progen-
itors (Oct4, Musashi-1) and are able to generate new neurons
and astrocytes in a medium containing EGF. The use of the
NF-κB inhibitor JSH-23 confirms that the observed dediffer-
entiation in the presence of TNF is clearly due to the activation
of the classical NF-κB pathway. Moreover, the use of highly
Fig. 6 Inflammation induces astrocyte dedifferentiation in vivo. a Stab
wound injury was executed with PBS in the right primary somatosensory
cortex using a Hamilton syringe (1 μl). 24 h, 48 h, and 5 days after stab
wound with PBS using a Hamilton syringe (1 μl), brains were collected,
sliced, and analyzed by immunofluorescence for the expression of GFAP
(red) and CD11b (green). Scale bar=500 μm. DAPI nucleus staining in
blue. b Stab wound injury was executed with PBS or LPS (1 μg/μl) or
TNF (10 ng/μl) in the right primary somatosensory cortex using a
Hamilton syringe (1 μl). Tissue samples were collected using a biopsy
patch and followed by RNA extraction, 24 h after wounding. Samples
were analyzed for the expression of Oct4 and CD44 by real-time PCR.
Gene expression has been normalized to β-actin. n=3 animals per exper-
imental group; error bars represent the SEM. *p<0.05 and ***p<0.001
for the main effect Bhemisphere^ in the two-way ANOVA (hemisphere×
treatment). c 24 h after stab wound with PBS using a Hamilton syringe
(1 μl), brains were collected, sliced, and analyzed by immunofluores-
cence for the expression of Oct4 (upper panel, green; middle and lower
panels, red), GFAP (upper panel, red), and J1-31 (anti-astrocyte
antibody) (middle and lower panels, green). Ipsilateral sides are com-
pared to contralateral sides. Scale bar=50 μm. DAPI nucleus staining
in blue. *p<0.05, ***p<0.001
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pure astrocyte cultures, derived from neurospheres, is arguing
that astrocytes themselves respond to TNF and that we do not
observe an indirect effect through a microglial cell release.
The conversion of somatic cells, like astrocytes, to a
multipotent state raises a central question: which regulator
triggers this process of dedifferentiation? Pluripotency is a
transient feature that becomes increasingly restricted during
development [38]. ESC self-renewal and differentiation are
tightly regulated by specialized transcription factors such as
Oct4, Sox2, and Nanog [18, 39]. Suppression of Oct4, Sox2,
and Nanog has been correlated with cell fate specification and
lineage-specific differentiation [40]. While Oct4 is highly
expressed in ESCs, it becomes silent upon differentiation.
Some studies show that Oct4 could be detected at a low level
in various progenitor cells and in somatic tissues [41]. Inter-
estingly, it has been shown that Oct4 is expressed in NSCs and
neural progenitor cells and that tuning its expression influ-
ences the cell fate. Thus, downregulating Oct4 accelerates
the neuronal differentiation of progenitor cells during devel-
opment, while its sustained expression prevents neuronal dif-
ferentiation [19]. Additionally, recent data demonstrate the
differential expression of Oct4 in neural stem cells grown
in vitro [42]. The authors found that the expression of Oct4
in the CNS is still active by E8.5 but declines rapidly until
becoming undetectable by E15.5. This decline coincides with
the gradual methylation of the Oct4 promoter and proximal
enhancer [18]. These results indicate that Oct4 is an essential
regulator of NSC differentiation during development. Recent-
ly, molecular beacons towards SOX2 and Oct4 mRNA were
successfully used to track gene expression in living
neurosphere cells [43]. In addition, recent studies show that
Oct4 is highly expressed in human gliomas as well as in gli-
oma cell lines, and that its expression level is positively
correlated to increasing glioma grades [15, 20]. In cell cul-
tures, it has been shown that Oct4 is expressed in rat C6
glioma cells and rat neural stem cells but not in differentiated
cells from the rat brain. Strikingly, overexpression of Oct4 in
C6 cells was able to increase the expression of Nestin and
Stat3 phosphorylation while decreasing the expression of
GFAP, which suggests that Oct4 might inhibit the differentia-
tion of glioma cells [20]. Amazingly, recently, the presence of
a rare population of Oct4-positive primitive neural stem cells
is observed in the periventricular region of the adult mice
forebrain whose progeny includes GFAP-positive type b cells
[44]. Taken together, these results demonstrate that Oct4 could
play a role not only in ESCs but also in more restricted pro-
genitors in the CNS.
Interestingly, we observed that the conversion of mature
astrocytes into progenitor-like cells correlated with the upreg-
ulation of Oct4 transcript levels, suggesting that Oct4might be
able to modulate the astrocyte phenotype in response to TNF.
In addition, the nuclear localization of Oct4 in reactive astro-
cytes suggests that it might be active. The re-expression of
Oct4 could be able to modulate the expression profile of as-
trocytes during TNF treatment. We tried to investigate this
hypothesis and used siRNA to silence Oct4. Unfortunately,
we failed to detect a significant change in these modulation
trends. We nevertheless provide these results in the supple-
mentary figure (SD4). Our observations sustain the central
role of Oct4 as described in glioma cells [20] and suggest that
the cellular mechanism occurring during the retinal regenera-
tion in zebrafish (re-induction of pluripotency factors like
Oct4 or Sox2 in Müller glia) could be partially conserved in
mammalian CNS [45]. Epigenetic modifications might ex-
plain the reactivation of Oct4. In fact, recent data show that
the activation of inflammatory pathways causes rapid and
Fig. 7 Effects of NF-κB inhibi-
tion on the dedifferentiation of
astrocytes. The NF-κB inhibitor
JSH-23 was added 30min prior to
24 h of TNF treatment on primary
astrocytes. Real-time PCR was
used to assess the regulation of
Oct4, CD44, IκBα, and EGFR.
Gene expression has been nor-
malized to β-actin. n=3; error
bars represent the SEM. *p<0.05
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global changes in the expression of epigenetic modifiers,
which enhance chromatin remodeling and nuclear
reprogramming [46]. For example, the microRNA-145, a
miRNA enriched in rat spinal neurons and astrocytes, is
downregulated after spinal cord injury [47]. It is known that
expression of microRNA-145 is low in self-renewing human
embryonic stem cells (hESCs) but highly upregulated during
differentiation and that the OCT4, SOX2, and KLF4 are direct
targets of miR-145 [48]. Then, we could hypothesize that the
downregulation of microRNA-145 might explain the reacti-
vation of Oct4 in inflammatory conditions.
This study uncovers the ability of astrocytes to undergo a
functional dedifferentiation in response to an inflammatory
stimulus. In fact, during an early response of reactive gliosis,
TNF can induce the dedifferentiation of astrocytes by the re-
expression of immaturity genes and the loss of marker of
mature astrocytes like GFAP or glycogen metabolism gene
expression. These dedifferentiated astrocytes are at least in
part behaving like neural progenitors. Thus, they are able to
proliferate in a medium containing EGF and can differentiate
into both neurons and astrocytes. The molecular mechanisms
underlying the dedifferentiation of astrocytes involve the
NF-κB pathway as well as the transcription factor Oct4. Our
model predicts that the re-expression of Oct4 modulates the
expression of CD44 and GFAP and engages the conversion of
a mature astrocyte to an immature state, which shares some
characteristics with neural progenitors. The data presented
here reveal the plasticity of astrocytes and a new role for
Oct4 in the control of the dedifferentiation process of mature
cells. Combining our results of the role of TNF in the dedif-
ferentiation of astrocytes with the results already available in
the literature enables us to propose a model of in vivo reactive
gliosis, which we describe in Fig. 8. Initial microglia activa-
tion during injury gives rise to the production of TNF, which
in turn induces the dedifferentiation of astrocytes. As long as
TNF is released, these dedifferentiated astrocytes remain in an
immature state in the vicinity of the injury. These
dedifferentiated astrocytes might be able to proliferate under
the stimulation of pathways like Wnt/β-catenin, SHH, EGF,
and bFGF [10, 49, 50]. Once TNF decreases, reactive astro-
cytes could differentiate again in response to IL-6-type cyto-
kines or the activation of the Notch signaling, and ultimately
express their typical marker, GFAP [51, 52]. It would be in-
teresting to investigate if the same dedifferentiation of astro-
cytes occurs in the facial nerve transection model, as it has
been described that the response of astrocytes occurs at dis-
tance in a less inflammatory environment [53].
This study uncovers a remarkable capability of astro-
cytes to undergo a dedifferentiation process in response
to a single change in their extracellular environment. Fi-
nally, our results suggest that the astrocytic dedifferenti-
ation process observed during inflammation could have
important implications on therapeutic strategies in injured
CNS regeneration, but might also represent a possible
trigger initiating the tumor conversion of glial cells in
the brain.
Fig. 8 Proposed model for the
role of TNF in the generation of
reactive glia during injury. An
initial microglia activation during
injury gives rise to TNF
production, which induces
astrocyte dedifferentiation. TNF
release maintains the
dedifferentiated astrocyte in an
immature state within the injury
area. In this immature state,
dedifferentiated astrocytes are
able to proliferate after the
stimulation of pathways like Wnt,
SHH, EGF, or bFGF. When TNF
decreases, reactive astrocytes
could re-differentiate and express
their typical marker, GFAP
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